Neoantigen vaccines are personalized cancer immunotherapies built around tumor-specific peptide sequences identified from each patient's mutated protein landscape. The platform sits at the intersection of next-gen sequencing, peptide-MHC presentation work, and lipid-nanoparticle or amphiphile delivery.
Leading programs covered on this site: BioNTech and Genentech's autogene cevumeran in pancreatic cancer (with long-term survival data), Evaxion's EVX-01 in melanoma, ELI-002 amphiphile-peptide vaccine for KRAS-mutant tumors, and earlier-stage academic work on neoantigen prediction with machine-learning prioritization. The Mel39 melanoma trial sits in the same family.
Stories here cover trial readouts, AACR and ASCO presentations, and the partnership economics. See #peptide-vaccine, #cancer-vaccine, and #mrna-vaccine for adjacent threads.
A Phase 1/2 study (NCT07637786) of ONVAX-01, a personalized peptide nanovaccine, in combination with an anti-PD-1 antibody and standard-of-care chemotherapy in patients with advanced pancreatic cancer began recruiting in late June 2026. The trial design has participants receive doses of the nanovaccine along with intravenous infusions of an anti-PD-1 checkpoint inhibitor plus chemotherapy, with serial imaging and blood-marker monitoring for tumor response. ONVAX-01 sits in the same broad therapeutic space as Elicio Therapeutics' ELI-002 7P (which missed its Phase 2 AMPLIFY-7P primary disease-free survival endpoint on June 15) but with a different delivery vehicle (nanoparticle self-assembly versus amphiphile-modified CpG oligonucleotide adjuvant). KRAS mutations drive approximately 90% of pancreatic ductal adenocarcinoma cases and 50% of colorectal cancers, making KRAS-targeting peptide vaccines one of the highest-impact unmet targets in solid-tumor oncology. The peptide nanovaccine modality has roots in 2022 case-report literature on neoantigen nanovaccine immunotherapy in advanced pancreatic cancer and broader nanovaccine work using DP7-C antimicrobial peptide as carrier-plus-adjuvant.
A Nature Biotechnology paper from a multi-institution collaboration introduced deep peptide recognition profiling (PRP) — a yeast-display platform integrated with protein-language models that maps T-cell receptor binding across the proteome for individual TCRs. Applied to HLA-B*27:05-restricted TCRs from patients with ankylosing spondylitis and acute anterior uveitis, the platform identified hundreds to over 6,000 unique peptide ligands per TCR and surfaced candidate autoantigens. Predicted binding scores correlated significantly with experimental T-cell activation across multiple TCRs. The model outperformed AlphaFold3 and tFold-TCR in predicting T-cell activation — meaningful for autoimmune-disease antigen discovery and personalized neoantigen cancer-vaccine design alike. The mechanistic implication: the CDR3β loop arches over the center of the HLA-B27-bound peptide and accounts for most contacts, with CDR3α positioned peripherally.
A 2026 Science Advances paper demonstrated that systematically changing the orientation and placement of a single cancer-targeting peptide within a vaccine construct leads to formulations that significantly enhance immune response. One specific vaccine design consistently outperformed others by shrinking tumors, extending animal survival, and generating larger numbers of highly active cancer-killing T-cells. The work is mechanistically important for the broader personalized neoantigen vaccine pipeline (Mount Sinai PGV001, BioNTech autogene cevumeran, Evaxion EVX-01) because peptide-orientation engineering has been an under-systematized variable in current vaccine designs. The findings provide a generalizable engineering principle that could inform second-generation neoantigen vaccine constructs heading into late 2026 and 2027.
Pharmacy Times ran a Ferry Ossendorp Q&A on May 5 walking through the mechanistic case for peptide-based cancer vaccines: T cells recognize small peptides presented on the surface of tumor cells, and synthetic peptides matched to tumor antigens can be used to vaccinate the immune system to recognize and target those tumors. Ossendorp's own work showed that knowledge of a tumor's antigen profile combined with peptide vaccination can protect against very aggressive tumors in animal models. The piece sits inside a 2026 peptide-vaccine pipeline with 31 active personalized cancer-vaccine trials registered (more than dendritic-cell or RNA-vaccine platforms), the BioVaxys MVP-S survivin program heading to ASCO 2026, the Greenwich GP2/GLSI-100 FLAMINGO-01 readout, and the BriaCell Bria-IMT Phase 3.
A 2026 Asia-Pacific Journal of Clinical Oncology review of the personalized cancer vaccine pipeline counts 31 active peptide-vaccine trials — the most-used personalized vaccine platform — followed by dendritic-cell vaccines (15) and RNA vaccines (13). Phase 1 trials dominate the landscape (over 90% of studies), with US (44%) and China (24%) leading by registration count. Solid tumors (brain, pancreatic, breast) are the primary targets. Lead programs covered on this site that fit the framework: ELI-002 KRAS amphiphile vaccine (AMPLIFY-201), autogene cevumeran (BioNTech/Genentech) in pancreatic cancer, EVX-01 (Evaxion) in melanoma, GP2/GLSI-100 (Greenwich) in HER2 breast cancer, ENA101 (Enara), MVP-S (BioVaxys) in ovarian, and the multipeptide melanoma vaccination 20-year survival data.
A Nature Biotechnology paper introduced a user-defined peptide library platform that enables sensitive detection of cancer antigens — relevant for both cancer immunotherapy target identification and neoantigen vaccine design. The platform allows researchers to design peptide pools customized to specific tumor types or HLA profiles, accelerating the antigen-discovery bottleneck in personalized cancer vaccine development. Builds on the same proteomic technology stack advancing across multiple peptide-vaccine programs at BioNTech, Genentech, and emerging neoantigen biotechs.
Recent reviews and real-world observation studies aggregate the state of peptide-vaccine immunotherapy for glioblastoma. A 2024 Nature Communications real-world observational study reported clinically meaningful outcomes for personalized peptide vaccines; the UCPVax + temozolomide trial (NCT04280848) showed 97% anti-TERT immune response, 48% epitope spread, median OS 17.9 months, and 26% alive at 2 years. The peptide-vaccine modality is one of multiple approaches (mRNA, dendritic cell, neoantigen) advancing alongside immune checkpoint blockade.
Evaxion's AI-designed personalized neoantigen peptide vaccine EVX-01 combined with Keytruda produced a 75% objective response rate at 2 years in advanced melanoma patients, with 86% of vaccine targets triggering de novo T-cell responses. Data were presented April 22 at AACR 2026; 3-year follow-up expected in H2 2026. The 86% target-hit rate demonstrates AI-designed peptide neoantigen selection maturing for cancer vaccines.
Nearly half of participants in a Phase 1 trial of BioNTech/Genentech's personalized mRNA neoantigen vaccine autogene cevumeran remain alive up to six years after treatment, with T-cell responses showing no signs of waning. Eight of 16 patients produced durable CD8+ T cells targeting tumor neoantigens after nine doses, with the immune memory still detectable at six-year follow-up. A Phase 2 trial is underway.